Abstract: Objective To explore the anemia incidence of cancer patients in our department and the treatment of chemotherapy-related anemia. Cancer-related fatigue and quality of life were evaluated before and after treatment. Methods The clinical data of 84 patients who had been treated in out department between Aug 2007 and Nov 2008 were collected. The incidence and degree of anemia were evaluated, and the relationship between chemotherapy. EPO or combined with iron agent. Hemoglobin level were detected after 8 weeks when treated with Therapeutic efficacy was evaluated and influence on cancer-related fatigue and quality of life. Results The incidence of anemia was 83.33%, mild anemia was recorded as 30.95%, moderate anemia was 30.95%, and severe anemia was 15.48%, life-threatening anemia was 5.95%. None anemia was 16.67%. Hemoglobin level were elevated (21.2±3.3)g/Lon average. EPO accompanied by intravenous iron supplementation significantly increase in hemoglobin compared with no iron. Brief Fatigue Inventory (BFI) and Functional Assessment of Cancer Therapy-General (FACT-G) showed that cancer-related fatigue and quality of life were improved obviously. Conclusion The anemia incidence in cancer patients is high, especially accompanied by chemotherapy. Anemia correlated significantly with the quality of life. Early intervention in anemia had clinical significance in cancer patients. Addition of intravenous iron to EPO increases hemoglobin response.